PERJETA is indicated for use in combination with Herceptin® (trastuzumab) and chemotherapy for the adjuvant treatment of patients with HER2+ early breast cancer (EBC) at high risk of recurrence.1
PROVIDE HER WITH 1 FULL YEAR (UP TO 18 CYCLES)*
OF PERJETA + HERCEPTIN-BASED ADJUVANT TREATMENT1
*Or until disease recurrence or unmanageable toxicity, whichever occurs first.
See how PERJETA + Herceptin-based therapy can be used prior to surgery.
Take a closer look at dosing and administration, including dose considerations and modifications.
Genentech can help get your patients access to multiple financial assistance programs.